Wearable Injectors market size was USD 6.51 billion in 2022!

Global Wearable Injectors market size was USD 6.51 billion in 2022 and it is forecasted to reach USD 19.90 billion by 2030. Wearable Injectors Industry's Compound Annual Growth Rate will be 15.2% from 2023 to 2030. Factors Impacting on Wearable Injectors MarketIncrease in the prevalence of chronic diseasesThe increase in the prevalence of chronic diseases such as cardiovascular diseases & cancer, diabetes, and the growth in the use of biologics such as monoclonal antibodies for the treatment of diseases is the key factor that drives the growth of the global wearable injectors market. The treatment of chronic diseases such as diabetes and cardiovascular disorders includes a daily or weekly intake of injectables, which highlights the need for and adoption of convenient and efficient injection technologies.According to the International Diabetes Federation, in 2019, around 463 million people are suffering from diabetes worldwide; this is expected to increase to 700 million by 2045. The increasing disease prevalence has prompted market players offering wearable injectors to focus on product launches, resulting in the introduction of products such as Amgen's Repatha Pushtronex system (using West Pharmaceutical's SmartDose Technology platform) and the Neulasta (pegfilgrastim) OnPro kit for the treatment of neutropenia in cancer. As disease prevalence increases in the coming years, the demand for effective and advanced treatment modalities such as wearable injectors will increase.Restraining Factors for Wearable Injectors Market:High cost of wearable injectors devicesHowever, the high cost associated with wearable injectors is expected to restrain the growth of the wearable injectors market. Wearable injectors are used as an alternative to requiring the patient to be admitted to a medical facility for clinical support. To achieve wide adoption, technology platforms need to minimize incremental cost increases to pharmaceutical companies,  and patients. Due to the higher cost of wearable injectors compared to oral medication or that delivered by an autoinjector, their adoption is lower among end users.Impact of the COVID-19 Pandemic on the Wearable Injectors Market:In the outbreak of covid 19, many patients have shifted their hospital care to home care, due to the strict lockdown across the countries which increases the demand for the wearable injectors market. Furthermore, the COVID-19 pandemic has boosted the demand for medical equipment and supplies including wearable injectors. Therefore, COVID-19 has had a  favourable impact on the global wearable injectors market. To stop the spread of the disease, the pandemic has encouraged the entire healthcare system to switch to home-based therapies. Additionally, considering the need for devices, the companies are focusing on the development and manufacturing of wearable injectors.Despite the challenges of COVID-19, there has been a great amount of progress in the digital transformation of the healthcare industry. With the progression of artificial intelligence and machine learning (AI/ML), the healthcare and medical device industries will diagnose disease better and earlier, treat illness more precisely, and engage patients more efficiently which will help to increase the demand for wearable injectors. Introduction of Wearable InjectorsThe increasing incidences of chronic diseases, the rising geriatric population, and growing concern over needle stick injuries are the factors that drive the growth of the market. Wearable injectors are drug-delivery devices that adhere to the body and automatically deliver preset doses to patients at optimal times. Unlike insulin pumps, wearable injectors are single-use systems that are comfortably worn on the body while the drug is subcutaneously administered over a pre-programmed period spanning seconds or hours. Upon full injection of the dose, they are removed from the body and conveniently disposed of. The development of such devices has been promoted by the concept of patient-centricity and an increased focus on human factors in drug delivery design.

全球可穿戴注射器市场规模于2022年达到65.1亿美元，预计到2030年将增长至199亿美元。2023年至2030年，可穿戴注射器行业的复合年增长率预计将达到15.2%。影响可穿戴注射器市场增长的因素包括慢性病（如心血管疾病、癌症、糖尿病）的患病率上升，以及生物制剂（如单克隆抗体）在疾病治疗中的应用增长。慢性疾病的治理，如糖尿病和心血管疾病，需要每日或每周注射药物，这凸显了对便捷高效注射技术的需求与采纳。根据国际糖尿病联盟的数据，2019年全球约有4.63亿人患有糖尿病，预计到2045年将增至7亿。疾病患病率的上升促使可穿戴注射器市场的主要参与者专注于产品发布，从而引入了如Amgen的Repatha Pushtronex系统（采用West Pharmaceutical的SmartDose技术平台）和Neulasta（聚乙二醇化粒细胞集落刺激因子）OnPro套件等治疗癌症中性粒细胞减少症的产品。随着未来几年疾病患病率的增加，对有效先进治疗方式（如可穿戴注射器）的需求也将增加。然而，可穿戴注射器的高昂成本预计将抑制市场增长。与口服药物或自动注射器相比，可穿戴注射器的成本更高，因此其终端用户的采纳率较低。COVID-19大流行对可穿戴注射器市场的影响：在COVID-19疫情爆发期间，由于各国实施的严格封锁，许多患者将医院护理转向家庭护理，这增加了对可穿戴注射器市场的需求。此外，COVID-19大流行推动了医疗设备和用品（包括可穿戴注射器）的需求。因此，COVID-19对全球可穿戴注射器市场产生了有利影响。为了阻止疾病的传播，大流行促使整个医疗保健系统转向基于家庭的疗法。此外，考虑到设备的需求，公司正专注于可穿戴注射器的研究和制造。尽管COVID-19带来了挑战，但医疗保健行业的数字化转型取得了巨大进展。随着人工智能和机器学习（AI/ML）的进步，医疗和医疗器械行业将能够更好地、更早地诊断疾病，更精确地治疗疾病，并更有效地参与患者管理，这将有助于增加对可穿戴注射器的需求。可穿戴注射器的引入：慢性病发病率的增加、老年人口的上升以及人们对针头刺伤的关注日益增加，这些因素推动了市场的发展。可穿戴注射器是一种粘附于身体的药物输送设备，能够在最佳时间自动向患者输送预设剂量的药物。与胰岛素泵不同，可穿戴注射器是单次使用的系统，可以在药物通过预先编程的秒或数小时内皮下给药的同时舒适地佩戴在身上。在完全注射剂量后，它们从身体上移除，并方便地丢弃。此类设备的发展得益于以患者为中心的理念和对药物输送设计中人因工程的重视。